Full Announcement Q2 upon completion but additional interim...

Was lucky enough to be Buying SNT @1.7c / 1.9c must say I was tempted to drop a few when we ran up to 9.5c but SNT is a Phoenix of PXS and they had completed some serious work surrounding attracting a partner previously..

Now that they are completing the Phase II for SNT 5505 they are actually in the deal zone,,, so I won't be selling any until after the SNT 5505 results are announced and bedded in , only if no Partner for either Commercialisation or the Phase III is cemented..

Usually as many know I'm a fixed margin Trader , my margin is loaded the day I buy... BUT SNT is not like any other Biotech.
1, it has 4 x Phase II Candidates,,, you will be very hard pressed to find another with such a diverse offering..
2, SNT 5505 and PXS /SNT 4728 Trials are in the final legs of trialing,,, so results are pending ,,, heck look how many get delayed on regulatory admin or even recruiting so if this was a 2400m race SNT 5505 and 4728 are on the home straight ..

3 My primary interest is in SNT 6302 ,,, this is a First In Class Medicine , there is NO COMPETITION , NO SOC (Standard of Care) so no incumbent to displace for total market domination.
Added to this the Primary Investigator is "Australian of the Year" and the Inventor or Liquid Skin , place being a world renowned cosmetic surgeon on top with a very low Regulatory bar for Dermal applications, Creams etc approval for Fiona would be a walk in the park,,
What actually shocked me was the way Gary casually added to the last presentation that "fiona has continued to trial SNT 6302 on burns grafts" that was a revelation in itself.
If you take the example of utilising SNT 6302 on Burns Grafts , skin Tears and Impact wounds plus Old Established Historical scars and she made the comment of "Unprecedented Results" you can extrapolate that out to now being applied to a "fresh surgical scalpel scar" , it's not to much of a stretch for the imagination to expect a tube of SNT 6302 to be going home with every single Hospital surgical patient.

To really add interest was that Gary stated "They had been in discussions with Cosmetic Surgeons" now that Industry is BIG TICKET...

So with Syntara out so far in front now ,my mandate on this one is "Wait for the full value to be extracted" sure when we enter the teens its going to be a test....

I really do not like comparing Biotechs as its like comparing Apples and Orangutans but SNT does seem to be destined for success...
Held RAC shares and thought after a 4 bagger was doing well then it ran to $4,,, with a single repurposed Drug..

SNT owns all of its own IP and has developed the drugs in house with 100% ownership no strings or partners attached with Fresh IP with a long protection period still in tact...

The only thing I see holding back SNT is lack of market Wide awareness and weak / poor market messaging , in some cases its like an afterthought??

Full Announcement Q2 upon completion but additional interim results were stated for March

Plus by end of March pretty sure that's the last of the Parkinson Patients Trial in the UK completed... (they have all completed dosing so Data Analysis is underway)

You would think the Company would be out in the market place waving a huge flag , priming the markets of incoming data?

Best of luck to all invested ,,, NZT